![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: LARP4 |
Gene summary for LARP4 |
![]() |
Gene information | Species | Human | Gene symbol | LARP4 | Gene ID | 113251 |
Gene name | La ribonucleoprotein 4 | |
Gene Alias | PP13296 | |
Cytomap | 12q13.12 | |
Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | Q6P4E2 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
113251 | LARP4 | CCI_2 | Human | Cervix | CC | 3.36e-09 | 1.05e+00 | 0.5249 |
113251 | LARP4 | CCI_3 | Human | Cervix | CC | 2.57e-04 | 6.18e-01 | 0.516 |
113251 | LARP4 | LZE4T | Human | Esophagus | ESCC | 3.52e-06 | 2.70e-01 | 0.0811 |
113251 | LARP4 | LZE7T | Human | Esophagus | ESCC | 1.10e-04 | 3.02e-01 | 0.0667 |
113251 | LARP4 | LZE8T | Human | Esophagus | ESCC | 3.07e-04 | 1.63e-01 | 0.067 |
113251 | LARP4 | LZE20T | Human | Esophagus | ESCC | 2.98e-06 | 3.60e-02 | 0.0662 |
113251 | LARP4 | LZE24T | Human | Esophagus | ESCC | 5.87e-07 | 3.08e-01 | 0.0596 |
113251 | LARP4 | P1T-E | Human | Esophagus | ESCC | 1.34e-07 | 4.66e-01 | 0.0875 |
113251 | LARP4 | P2T-E | Human | Esophagus | ESCC | 7.72e-26 | 7.43e-01 | 0.1177 |
113251 | LARP4 | P4T-E | Human | Esophagus | ESCC | 1.15e-20 | 6.70e-01 | 0.1323 |
113251 | LARP4 | P5T-E | Human | Esophagus | ESCC | 1.02e-14 | 4.13e-01 | 0.1327 |
113251 | LARP4 | P8T-E | Human | Esophagus | ESCC | 7.93e-27 | 5.06e-01 | 0.0889 |
113251 | LARP4 | P9T-E | Human | Esophagus | ESCC | 2.14e-06 | 1.98e-01 | 0.1131 |
113251 | LARP4 | P10T-E | Human | Esophagus | ESCC | 4.99e-23 | 3.67e-01 | 0.116 |
113251 | LARP4 | P11T-E | Human | Esophagus | ESCC | 1.88e-06 | 3.58e-01 | 0.1426 |
113251 | LARP4 | P12T-E | Human | Esophagus | ESCC | 7.56e-07 | 3.07e-01 | 0.1122 |
113251 | LARP4 | P15T-E | Human | Esophagus | ESCC | 2.09e-17 | 4.21e-01 | 0.1149 |
113251 | LARP4 | P16T-E | Human | Esophagus | ESCC | 6.07e-25 | 3.99e-01 | 0.1153 |
113251 | LARP4 | P17T-E | Human | Esophagus | ESCC | 2.53e-02 | 1.69e-01 | 0.1278 |
113251 | LARP4 | P19T-E | Human | Esophagus | ESCC | 1.61e-03 | 6.53e-01 | 0.1662 |
Page: 1 2 3 4 5 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:002260410 | Cervix | CC | regulation of cell morphogenesis | 84/2311 | 309/18723 | 1.00e-12 | 4.29e-10 | 84 |
GO:003133010 | Cervix | CC | negative regulation of cellular catabolic process | 63/2311 | 262/18723 | 1.10e-07 | 5.68e-06 | 63 |
GO:00064029 | Cervix | CC | mRNA catabolic process | 56/2311 | 232/18723 | 4.81e-07 | 1.83e-05 | 56 |
GO:19033119 | Cervix | CC | regulation of mRNA metabolic process | 64/2311 | 288/18723 | 1.71e-06 | 5.64e-05 | 64 |
GO:000989510 | Cervix | CC | negative regulation of catabolic process | 69/2311 | 320/18723 | 2.15e-06 | 6.55e-05 | 69 |
GO:00064019 | Cervix | CC | RNA catabolic process | 62/2311 | 278/18723 | 2.18e-06 | 6.56e-05 | 62 |
GO:003425010 | Cervix | CC | positive regulation of cellular amide metabolic process | 40/2311 | 162/18723 | 1.11e-05 | 2.41e-04 | 40 |
GO:000641710 | Cervix | CC | regulation of translation | 89/2311 | 468/18723 | 1.86e-05 | 3.46e-04 | 89 |
GO:004572710 | Cervix | CC | positive regulation of translation | 33/2311 | 136/18723 | 9.09e-05 | 1.20e-03 | 33 |
GO:00610139 | Cervix | CC | regulation of mRNA catabolic process | 38/2311 | 166/18723 | 1.07e-04 | 1.36e-03 | 38 |
GO:190331210 | Cervix | CC | negative regulation of mRNA metabolic process | 24/2311 | 92/18723 | 2.49e-04 | 2.77e-03 | 24 |
GO:00467008 | Cervix | CC | heterocycle catabolic process | 80/2311 | 445/18723 | 3.23e-04 | 3.42e-03 | 80 |
GO:00346559 | Cervix | CC | nucleobase-containing compound catabolic process | 74/2311 | 407/18723 | 3.77e-04 | 3.88e-03 | 74 |
GO:00434889 | Cervix | CC | regulation of mRNA stability | 35/2311 | 158/18723 | 3.80e-04 | 3.89e-03 | 35 |
GO:00434879 | Cervix | CC | regulation of RNA stability | 36/2311 | 170/18723 | 7.72e-04 | 6.86e-03 | 36 |
GO:00442709 | Cervix | CC | cellular nitrogen compound catabolic process | 79/2311 | 451/18723 | 7.80e-04 | 6.91e-03 | 79 |
GO:19023698 | Cervix | CC | negative regulation of RNA catabolic process | 19/2311 | 75/18723 | 1.54e-03 | 1.19e-02 | 19 |
GO:00194398 | Cervix | CC | aromatic compound catabolic process | 79/2311 | 467/18723 | 2.14e-03 | 1.54e-02 | 79 |
GO:19013618 | Cervix | CC | organic cyclic compound catabolic process | 80/2311 | 495/18723 | 6.77e-03 | 3.72e-02 | 80 |
GO:19023738 | Cervix | CC | negative regulation of mRNA catabolic process | 15/2311 | 63/18723 | 8.52e-03 | 4.40e-02 | 15 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LARP4 | SNV | Missense_Mutation | novel | c.418N>A | p.Glu140Lys | p.E140K | Q71RC2 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-NJ-A4YP-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
LARP4 | SNV | Missense_Mutation | c.1946N>A | p.Ser649Tyr | p.S649Y | Q71RC2 | protein_coding | deleterious(0.02) | possibly_damaging(0.8) | TCGA-NJ-A4YP-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
LARP4 | SNV | Missense_Mutation | novel | c.1025N>T | p.Glu342Val | p.E342V | Q71RC2 | protein_coding | deleterious(0.02) | possibly_damaging(0.902) | TCGA-21-A5DI-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
LARP4 | SNV | Missense_Mutation | c.1405C>G | p.Pro469Ala | p.P469A | Q71RC2 | protein_coding | deleterious(0.01) | benign(0.361) | TCGA-37-4141-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
LARP4 | SNV | Missense_Mutation | novel | c.943N>T | p.Pro315Ser | p.P315S | Q71RC2 | protein_coding | tolerated(0.18) | benign(0.284) | TCGA-56-7579-01 | Lung | lung squamous cell carcinoma | Male | <65 | III/IV | Chemotherapy | carboplatin | PD |
LARP4 | SNV | Missense_Mutation | novel | c.1657N>A | p.Pro553Thr | p.P553T | Q71RC2 | protein_coding | deleterious(0.01) | benign(0.019) | TCGA-66-2734-01 | Lung | lung squamous cell carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
LARP4 | SNV | Missense_Mutation | novel | c.964N>G | p.Gln322Glu | p.Q322E | Q71RC2 | protein_coding | deleterious(0.04) | probably_damaging(0.972) | TCGA-CR-7402-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | carboplatin | SD |
LARP4 | SNV | Missense_Mutation | c.1999G>T | p.Val667Phe | p.V667F | Q71RC2 | protein_coding | tolerated(0.16) | benign(0.113) | TCGA-CV-7410-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | III/IV | Unknown | Unknown | PD | |
LARP4 | SNV | Missense_Mutation | novel | c.260A>G | p.Asn87Ser | p.N87S | Q71RC2 | protein_coding | tolerated(0.27) | benign(0.044) | TCGA-DQ-5630-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
LARP4 | SNV | Missense_Mutation | novel | c.1889N>C | p.Gln630Pro | p.Q630P | Q71RC2 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-ZG-A9LZ-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |